Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
382 studies found for:    Expanded Access Studies
Show Display Options
Rank Status Study
21 Available C11 Sodium Acetate PET/CT Imaging of PCa
Condition: Prostate Cancer
Intervention: Drug: Carbon-11 Sodium Acetate
22 Available Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock
Conditions: Septic Shock;   Endotoxemia
Intervention: Device: TORAYMYXIN PMX-20R
23 Available Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Conditions: Neoplasms;   Carcinoma, Non-Small-Cell Lung
Intervention: Drug: crizotinib
24 Available Study of Allogeneic EBV-CTLs in EBV-Associated Viremia or Malignancies
Conditions: Epstein-Barr Virus-Associated Lymphoproliferative Disorder;   Epstein-Barr Virus Lymphoma;   Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder;   Epstein-Barr Virus-Associated Viremia
Intervention: Biological: Epstein-Barr Virus Cytotoxic T Lymphoctyes (EBV-CTLs)
25 Available Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Ocrelizumab
26 Available Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Abemaciclib
27 Available An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: Brigatinib
28 Available Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury
Conditions: Cholestasis;   Total Parenteral Nutrition-induced Cholestasis
Intervention: Drug: Omegaven
29 Available Compassionate Use of Omegaven
Condition: Cholestasis
Intervention: Dietary Supplement: Omegaven
30 Approved for marketing Expanded Access of Pimavanserin for Patients With PD Psychosis
Condition: Parkinson's Disease Psychosis
Intervention: Drug: Pimavanserin tartrate
31 Temporarily not available An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
Condition: HIV
Intervention: Drug: PRO 140
32 No longer available Expanded Access to ANG1005 for Individual Patients
Conditions: Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Breast Cancer With Recurrent Brain Metastases;   Leptomeningeal Carcinomatosis
Intervention: Drug: ANG1005
33 Available Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Condition: Fecal Incontinence
Intervention: Device: magnetic anal sphincter augmentation for fecal incontinence
34 Available Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Condition: Non-Hodgkin's B-cell Lymphoma
Intervention: Drug: MT-3724
35 No longer available SARC021C: A Continuation Study of TH-CR-406/SARC021
Condition: Soft Tissue Sarcoma
Intervention: Drug: Th-302
36 Available Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
Condition: Midgut Carcinoid Tumor
Intervention: Drug: 177Lu-DOTA0-Tyr3-Octreotate
37 Available Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma
Condition: Urothelial Carcinoma Ureteral Location
Intervention: Drug: MitoGel
38 Available Low-profile Visualized Intraluminal Support -HUD
Condition: Giant Wide Necked Aneurysms
Intervention: Device: Low Profile Visualized Intraluminal Support Device
39 Approved for marketing Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries
Condition: Peripheral Arterial Disease
Intervention: Device: Atherectomy followed by Drug Eluting Balloon (DEB)
40 Available Expanded Access Protocol Using HBOC-201
Condition: Anemia
Intervention: Biological: HBOC-201

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.